奥阿巴因介导的IGF2BP2-GLS/NOS3轴影响扩散大B细胞淋巴瘤中阿金因代谢
Yuxin Hong1, Hehua Ma2, Zhuoling Zhao1
1Phase I Clinical Trials Unit, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210023, China.
European journal of medical research
|October 10, 2025
概括
奥阿巴因通过通过IGF2BP2,GLS和NOS3.3改变氨酸代谢,使扩散性大B细胞淋巴瘤 (DLBCL) 恶化. 针对这种途径为DLBCL治疗提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 代谢学 代谢学 代谢学
- 分子生物学分子生物学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 恶性进展与乌阿巴因和胰岛素样生长因子2mRNA结合蛋白 (IGF2BP2) 有关.
- 奥阿巴因对DLBCL的代谢影响在很大程度上仍未被探索.
研究的目的:
- 为了研究ouabain和IGF2BP2对DLBCL代谢的影响.
- 确定关键的代谢途径和参与DLBCL进展的基因.
主要方法:
- 用ouabain治疗或IGF2BP2敲除的DLBCL细胞的非向代谢分析.
- 使用实时定量PCR (RT-qPCR) 进行基因表达分析.
- 功能性检测包括细胞增殖,细胞循环和细胞亡研究.
主要成果:
- 奥阿巴因和IGF2BP2倒置改变了DLBCL细胞中的阿尔金因代谢途径.
- 氧化合成酶3 (NOS3) 和谷氨酸酶 (GLS) 被确定为阿尔金因代谢中的关键基因,在DLBCL中高度表达,与生存率差相关.
- IGF2BP2调节了NOS3和GLS的表达;干扰GLS和NOS3抑制了增殖,延迟了细胞周期,并促进了细胞亡.
结论:
- 奥阿巴因通过IGF2BP2-GLS/NOS3轴扰乱阿尔金因代谢,从而影响DLBCL的进展.
- IGF2BP2-GLS/NOS3通路代表了DLBCL治疗的潜在治疗标.
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
NF-κB-dependent Signaling Pathway
9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.8K
Receptor Downregulation in MVBs
2.8K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.8K
The Nucleolus
10.3K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.3K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K


